SCHEMBL30633892

SCHEMBL30633892

O/N=C(\c1c(Cl)cccc1Cl)N1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.49
KDM4E B2RXH2 3/20 0.47
GRM5 P41594 1/20 0.46
ADRB1 P08588 1/20 0.45
MAPT P10636 3/20 0.44
GAA P10253 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RAB9A P51151 2/20 0.43
MAPK1 P28482 2/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
GLA P06280 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23064314 1.00 AKR1C3 (0.49) AKR1C3KDM4EGRM5ADRB1MAPT
SCHEMBL31050090 1.00 AKR1C3 (0.49) AKR1C3KDM4EGRM5ADRB1MAPT
SCHEMBL23064354 1.00 AKR1C3 (0.49) AKR1C3KDM4EGRM5ADRB1MAPT
SCHEMBL23701855 0.84 AKR1C3 (0.46) AKR1C3KDM4EGRM5ADRB1MAPT
SCHEMBL31050100 0.84 AKR1C3 (0.46) AKR1C3KDM4EGRM5ADRB1MAPT
SCHEMBL23064291 0.84 AKR1C3 (0.46) AKR1C3KDM4EGRM5ADRB1MAPT
SCHEMBL30778026 0.84 AKR1C3 (0.46) AKR1C3KDM4EGRM5ADRB1MAPT
SCHEMBL30778024 0.83 CYP1A2 (0.47) AKR1C3KDM4EGRM5MAPTGAA
SCHEMBL27212322 0.80 RORC (0.45) AKR1C3KDM4EGRM5MAPTGAA
SCHEMBL23064386 0.79 TRPA1 (0.51) KDM4EMEN1KMT2ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170116-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE OSAKA UNIVERSITY (JP) 2025-05-29 US disclosed
US-20250073229-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE SHINSHU UNIVERSITY (JP) 2025-03-06 US disclosed
CN-118678955-A Pharmaceutical composition for preventing and/or treating heart failure 国立大学法人大阪大学 2024-09-20 CN disclosed
US-20240307375-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR KYOTO UNIVERSITY (JP) 2024-09-19 US disclosed
CN-112204017-B Benzisoxazole compounds 国立大学法人大阪大学 2024-08-20 CN disclosed
EP-3789383-B9 INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL UNIV OSAKA (JP) 2024-02-28 EP disclosed
CN-117580577-A Pharmaceutical composition for preventing and/or treating kidney injury and autophagy activator 国立大学法人大阪大学 2024-02-20 CN disclosed
EP-3789383-B1 INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL UNIV OSAKA (JP) 2023-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240307375-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR ATG7, BECN1, SQSTM1 AKR1C3 118/4885KDM4E 2158/4885GRM5 4014/4885
US-20250170116-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE REN, ATP6V1B1, CYP2S1 AKR1C3 17/4885KDM4E 3121/4885GRM5 3908/4885
US-20250073229-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE CBR1, CYP2S1, CYP2F1 AKR1C3 83/4885KDM4E 2741/4885GRM5 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.